Artemio Payá

TL;DR: The revised Bethesda guidelines constitute a useful approach to identify patients at risk for HNPCC in patients fulfilling these criteria, and both microsatellite instability testing and immunostaining are equivalent and highly effective strategies to further select those patients who should be tested for MSH2/MLH1 germline mutations.

TL;DR: Benefit from 5-FU adjuvant chemotherapy depends on the MMR status of tumours in patients with colorectal cancer but this benefit from chemotherapy cannot be extended to patients with MMR deficient tumours.

TL;DR: The risk of cancer in families of patients with LLS is lower that of families with Lynch syndrome but higher than that offamilies with sporadic CRC, confirming the need for special screening and surveillance strategies for these patients and their relatives.

TL;DR: In a cohort of colorectal cancer patients, those with MMR-deficient tumours seem not to benefit from 5-FU-based chemotherapy.

TL;DR: Patients with CIMP-positive colorectal tumors do not benefit from 5-FU-based adjuvant chemotherapy and are not an independent predictor of outcome.